Opendata, web and dolomites

mfloDx SIGNED

Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 mfloDx project word cloud

Explore the words cloud of the mfloDx project. It provides you a very rough idea of what is the project "mfloDx" about.

prescriptions    time    close    recommend    2024    33    forms    months    15    organization    accurate    costly    first    urgently    recommended    diagnoses    million    stop    world    global    rate    983    power    92    addressable    alarming    killed    patient    commercial    rapid    96    estimates    suffering    identification    strains    infections    mflodx    showed    infects    untreatable    patients    flourishing    faulty    32k    spread    generation    worldwide    regimens    unnecessary    pilot    curtail    market    drug    thereby    frac14    mid    grow    undergo    2015    incorrect    countries    health    antibiotics    times    euros    people    prescription    platform    tuberculosis    expenditure    population    diagnosis    suggest    inappropriate    tools    2000    bacteria    tbplus    projected    billion    100    efficiency    reduce    tb    resistant    treatment    diagnostic    trained    minimdr    incomplete    lag    detection    care    point    hours    income    afflicted    six    prevent    thousands    antibiotic    treatments    tens    molecular    treat    tests    diagnostics    specificity    appropriate    mdr    life    spreading    2030   

Project "mfloDx" data sheet

The following table provides information about the project.

Coordinator
EMPE DIAGNOSTICS AB 

Organization address
address: KAROLINSKA ISTITUTE SCIENCE PARK NOBELS VAG 16
city: STOCKHOLM
postcode: 171 65
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMPE DIAGNOSTICS AB SE (STOCKHOLM) coordinator 50˙000.00

Map

 Project objective

Tuberculosis (TB) killed 33 million people worldwide in 2000-2015 and infects an estimated ¼ of the world population. Drug-resistant forms of TB are flourishing at an alarming rate due to faulty diagnosis and widespread prescription of incorrect antibiotics. Rapid and accurate detection of multi-drug resistant (MDR) strains is urgently needed to effectively treat patients and prevent spreading of untreatable TB forms. Simple, low cost diagnostic tools are needed to enable point-of-care testing in low- and mid-income countries. mfloDx is a low-cost, simple diagnostic platform that can identify close to 100% of drug resistant TB cases. Pilot tests of the first product, miniMDR-TB, showed the efficiency and specificity to be 92-96% in agreement with that of another molecular test recommended by the World Health Organization. Our next-generation mfloDx products, MDR-TB and MDR-TBplus, are expected to have close to 100% MDR-TB identification power. The low cost of mfloDx tests will enable market uptake in highly afflicted developing countries, and thereby help to stop the loss of life, the spread of antibiotic-resistant infections, and prevent unnecessary costs. Projected global expenditure on diagnosis and treatment of TB will reach €983 billion between 2015-2030. The addressable market for TB diagnostics is projected to grow to €3.1 billion by 2024. Available commercial diagnostics for MDR-TB often deliver incomplete diagnoses and require long lag times, costly equipment (€15-32K), and highly trained personnel to recommend prescriptions. As a result, less than one-third of new TB patients undergo testing to determine appropriate antibiotic treatments. Our estimates suggest that mfloDx would reduce the treatment costs per MDR-TB patient by tens of thousands of euros and diagnosis time from about six months to two hours. This would avoid costly and inappropriate antibiotic regimens, reduce patient suffering, and curtail the spread of drug-resistant bacteria.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MFLODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MFLODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Yodiwo FEMP (2019)

An eco-friendly, Integrated Facility and Energy Management Platform for continuous reduction of infrastructure operating cost, driven by AI.

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More